Cipla Share Price Today, June 22, 2026: Stock Surges 3.62% to Rs 1,400.80
- June 22, 2026
- Posted by: Neeraj Pandey
- Category: News
CIPLA CMP Rs 1,400.80, up 3.62%. Prev close Rs 1,351.80. High Rs 1,403. Low Rs 1,370.60. Pharma momentum drives sharp gains today.
Cipla share price jumped 3.62% to Rs 1,400.80 on June 22, 2026, making it one of the top gainers in the pharmaceutical sector today. The Mumbai-based drug maker is among the most searched share prices on Google with over 500 active queries as the stock approaches its 52-week high range. The session high was Rs 1,403 and the low was Rs 1,370.60, with the previous close at Rs 1,351.80.
Cipla is one of India’s largest pharmaceutical companies, with a diversified portfolio spanning branded generics in India, regulated markets in the US and Europe, and emerging market businesses across Africa and South Asia. The company has been delivering consistent performance, with its US generics pipeline and India prescription business driving earnings growth.
Click Here – Get Free Investment Predictions
Cipla Share Price: Live Data for June 22, 2026
| Metric | Value |
|---|---|
| NSE Symbol | CIPLA |
| CMP | Rs 1,400.80 |
| Change | +3.62% |
| Previous Close | Rs 1,351.80 |
| Day’s High | Rs 1,403.00 |
| Day’s Low | Rs 1,370.60 |
| Sector | Pharmaceuticals |
| Market Cap | Large Cap |
Top Pharma Stocks on Analysts’ Research List on Univest
When Univest analysts identify high-conviction stock opportunities, investors pay attention.
Our research team has shortlisted the Top Stocks to Buy based on current market momentum, sector trends & growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks on Univest
Cipla share price has been on a strong upward trajectory over the past year, supported by the company’s improving US generics business, strong India prescription market execution, and a clean regulatory track record with the USFDA. The company’s focus on differentiated and complex generics in the US market is helping it sustain pricing power in an otherwise competitive generics environment.
The respiratory drugs segment, particularly the US inhaler products pipeline, is a key long-term value driver for Cipla. The company has been working on multiple complex respiratory formulations including generic versions of branded US inhalers, which, upon approval, could provide significant revenue uplifts given the large size of the US respiratory market.
Why Cipla Share Price Is Surging Today
Three factors are driving Cipla share price 3.62% higher today. Investors can use the Univest Screener to track CIPLA’s live fundamentals and compare it with pharma sector peers including Sun Pharma, Dr Reddy’s, and Divi’s Labs.
Track Cipla and Pharma Sector Stocks on Univest Screener
1. Pharma Sector Re-Rating and Positive Momentum
The Indian pharmaceutical sector is experiencing a broad re-rating as investors recognise the structural growth in domestic prescription volumes, improving US FDA inspection outcomes, and the global trend toward generic drug adoption. Cipla share price is benefiting from this sector-wide momentum, with institutions and retail investors both participating in the rally.
2. US Generics Pipeline Progress
Cipla’s US generics business has been a key earnings growth driver, with multiple ANDA approvals and product launches in recent quarters. The company’s focus on limited competition generics and complex respiratory products provides better pricing sustainability than commodity generic drugs, supporting both revenue and margin expansion.
3. India Prescription Business Strong Growth
Cipla’s India business, which spans branded generics across cardiovascular, respiratory, anti-infective, and oncology segments, has been consistently growing above industry averages. The company’s strong field force, doctor relationships, and brand equity in key therapeutic categories are driving market share gains in the domestic formulations market.
What Investors Should Watch for Cipla Share Price
The most important near-term triggers for Cipla share price are Q1 FY27 results in July and any USFDA announcements on complex respiratory product approvals. Investors should also monitor the company’s commentary on US price erosion trends in the generics segment.
Long-term investors tracking Cipla share price should watch the progress of the US inhaler products pipeline and the company’s expanding biosimilars portfolio. A successful launch of a complex respiratory product in the US could be a significant re-rating catalyst for the stock.
Conclusion
Cipla share price surged 3.62% to Rs 1,400.80 on June 22, 2026, driven by pharma sector momentum and positive investor outlook on the company’s US generics pipeline and India prescription growth. The stock is one of the top performing large-cap pharma names today. This article is for informational purposes only. Consult a SEBI-registered financial advisor before making investment decisions.
Download the Univest iOS App or Univest Android App to track Cipla share price live and access pharmaceutical sector stock research.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is Cipla share price today?
Ans. Cipla share price is Rs 1,400.80 on June 22, 2026, up 3.62% from the previous close of Rs 1,351.80. The day high is Rs 1,403 and the day low is Rs 1,370.60. Cipla trades on NSE under the symbol CIPLA.
Why is Cipla share price rising today?
Ans. Cipla share price is rising today due to broad pharma sector momentum, positive investor outlook on the company’s US generics pipeline, and strong India prescription business performance. The stock is also benefiting from sector-wide institutional buying in pharmaceutical companies.
What is Cipla’s main business?
Ans. Cipla is a pharmaceutical company that manufactures and sells branded generic medicines in India, generic drugs in the US and other regulated markets, and formulations in emerging markets across Africa and South Asia. Its key segments include India prescription, North America generics, and international branded formulations.
What is Cipla’s US inhaler pipeline?
Ans. Cipla has been developing complex generic inhalers for the US market that are bioequivalent to major branded respiratory drugs. These are difficult-to-formulate products with limited generic competition, which provides Cipla with better pricing and margin potential compared to standard generics upon USFDA approval.
Is Cipla a good stock to buy?
Ans. Cipla is one of India’s most respected pharmaceutical companies with a strong regulatory track record, diversified market presence, and a growing complex generics pipeline. Whether it suits your portfolio depends on your investment horizon and view on the pharma cycle. This is not investment advice. Consult a SEBI-registered advisor.
What is CIPLA’s USFDA status?
Ans. Cipla has a generally good track record with USFDA inspections across its manufacturing plants. Investors should verify the current status of any outstanding inspection observations or Warning Letters via the USFDA’s official website or the company’s latest investor communications.
What are the risks for Cipla investors?
Ans. Key risks include US generics price erosion, USFDA regulatory actions at manufacturing facilities, competition in the India branded generics market, currency risk from dollar revenue, and clinical or approval delays for complex product filings including respiratory inhalers.
Where can I track Cipla share price live?
Ans. Cipla share price can be tracked live on NSE at nseindia.com using the symbol CIPLA. The Univest app and Univest Screener provide live data and sector research on Cipla and other pharmaceutical stocks.
